Clinical Trial Update: 177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating 177Lu-FAP-2286 for metastatic or unresectable bladder urothelial cancer; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• 177Lu-FAP-2286

Snippet

Sponsor: Ankara University | Conditions: Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable | Phase 2 | Status: NOT_YET_RECRUITING